References
- Endimiani A, Perez F, Bonomo R. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 2008;6:805–24.
- US Food and Drug Administration. Center for drug evaluation and research. Medical review maxipime; application number 50-679/S007;p1–45. http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50679S007_Maxipine_medr.pdf (Accessed on: 10-09-2009).
- Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, . 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–51.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prevention and treatment of Cancer-related infections. V2.2009; p1-107. Available at: http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf (Accessed on: 10-09-2009).
- Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997–2000). Int J Antimicrob Agents 2003;21:1–7.
- Mebis J, Goossens H, Berneman Z. A 10-year follow-up of bacterial epidemiology and susceptibility patterns among febrile neutropenic adult patients with hematological malignancy. Klastersky J.A.. Conference Proceedings of the 11th International Symposium on Febrile Neutropenia. Georgia, USA: Imedex. Abstract p-0008.
- Ko WC, Hsueh PR. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002–2006. J Infect 2009;59:95–103.
- Drago L, De Vecchi E. The safety of cefepime in the treatment of infection. Expert Opin Drug Saf 2008;7:377–87.
- Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008;42:1843–50.
- Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176–89.
- Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:338–48.
- Nguyen T, Williams B, Trang E. Cefepime therapy and all-cause mortality. Clin Infect Dis 2009;48;902–4.
- Sanz MA, Lopez J, Lahuerta JJ, Rovira M, Batlle M, Pérez C, . Cefepime plus amikacin versus piperacillin–tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002;5:79–88.
- Glasmacher A, Von Lilienfeld-Toal M. An evidence based review of the available antibiotic treatment options for neutropenic patients and a recommendation for treatment guidelines. Int J Infect Dis 2006;10:S9–16.
- Towne T, Lewis J, Echevarria K. Efficacy and safety of cefepime. Lancet Infect Dis 2009;9:4–5.
- Mebis J, Vandeplassche S, Goossens H, Berneman ZN. Cefepime and amikacin as empirical therapy in patients with febrile neutropaenia: a single-centre phase II prospective survey. Acta Clin Belg 2009;64:35–41.
- US Food and Drug Administration. Center for Drug Evaluation and Research. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm167358.htm (Accessed on: 28-01-2010).
- Mebis J, Goossens H, Bruyneel P, Sion JP, Meeus I, Van Droogenbroeck J, . Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 1998;12:1627–9.